Russian biosimilar developer Biocad has won a legal battle that will allow it to move forward with its rituximab biosimilar.
Russian biosimilar developer Biocad has won a legal battle that will allow it to move forward with its rituximab biosimilar.
The Pharma Letter reports that Biocad triumphed in a patent dispute over rituximab with Swiss drug developer and maker of the reference rituximab (Rituxan, MabThera), Roche. The Russian government’s Chamber for Patent Disputes announced that Roche—Genentech’s patent covering the use of rituximab in rheumatoid arthritis was invalid. The ruling clears the way for Biocad to produce and commercialize a biosimilar of the anti–tumor necrosis factor agent that is used in the treatment of both cancer and rheumatologic diseases.
In June, Biocad gained authorization to market the biosimilar rituximab as Usmal in Bolivia and Honduras, and has already begun selling the drug in 7 other markets, including Kazakhstan, Vietnam, and Sri Lanka.
Biocad also announced its intentions to enter the European marketplace with both its innovator and biosimilar products, and said that it expects to receive marketing authorization from the European Medicines Association beginning in 2021. According to Biocad, the company is ready to provide dossiers of its medicines that align with the International Council for Harmonization Common Technical Document format. In May, Biocad took its first steps toward European market entry when it established a new Eurozone presence in Turku, Finland. Biocad plans to invest €25 million (approximately $28 million) in Finland’s Turku region over the next 7 years as it continues to develop products for the European market.
Despite its legal gains in Russia and its eye on global expansion, Biocad still faces hurdles to entering the United States market; in 2016, Biocad filed suit in a New York district court alleging that competitor Roche and other drug makers were engaged in an anticompetitive scheme that blocked Biocad from entering the US oncology drug marketplace. Biocad alleged that its competitors were increasing the prices of their drugs in the United States while selling the same products at deep discounts in Russia.
The judge dismissed the case, saying that US antitrust laws do not extend to conduct in Russia, and the effect of the activities in Russia on the United States market were too attenuated for the court to have jurisdiction over the claims.
Targeted Reimbursement Encourages Oncology Biosimilar Use
May 7th 2025Incentivizing physicians with modest financial bonuses may seem like a small step, but in Japan’s outpatient oncology setting, it helped push trastuzumab biosimilars toward broader adoption, demonstrating how even limited reimbursement reforms can reshape prescribing behavior under the right conditions.
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
Samsung Bioepis Report Signals Turning Point for US Biosimilars
May 1st 2025A wave of biosimilar approvals, aggressive pricing strategies, and a regulatory sea change are setting the stage for unprecedented momentum in the US biologics market, with 2025 already proving to be a landmark year in reshaping cost, access, and innovation across therapeutic areas.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Biosimilar Market Development Requires Strategic Flexibility and Global Partnerships
April 29th 2025Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to development strategies to overcome uncertainty and drive future success.